The US Food and Drug Administration (FDA) has granted approval for Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in ...

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide, with over 70% of patients diagnosed at ...

Randomized controlled trials are also needed to determine whether statins can actually reduce the risk for hepatocellular ...

Researchers sought to test the performance of a deep learning model system using longitudinal magnetic resonance imaging (MRI) in predicting early recurrence in patients with hepatocellular carcinoma.

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

Learn how nonalcoholic fatty liver disease develops, its warning signs, and the steps to help safeguard the liver.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

MARTINSBURG, WV — WVU Medicine Berkeley Medical Center is now offering a new treatment for liver cancer, according to a ...

Bristol Myers Squibb (BMS) has announced that its dual immunotherapy combination has been approved by the US Food and Drug ...

Statins appeared to reduce the risk for hepatocellular carcinoma and hepatic decompensation among patients with chronic liver ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

Regular junk food consumption, laden with unhealthy fats and sugars, significantly threatens liver health, leading to ...